SubsidieMeestersTranscatheter Ventricular Repair Device for treatment of Heart Failure Patients
Cardiac Success aims to develop the V-sling, a transcatheter device to enhance heart function in heart failure patients, through product optimization and pre-clinical testing.
Projectdetails
Introduction
Heart failure (HF) represents a major public health concern, affecting around 13 million people worldwide. A major risk factor for HF is a myocardial infarction, which causes ventricular remodeling. During this process, the ventricle enlarges, making the heart even less effective at pumping blood, and results in the displacement of the papillary muscle.
Impact of Papillary Muscle Displacement
Progressive papillary muscle displacement leads to severe Functional Mitral Regurgitation (FMR) in about 20% of the patients. These patients are the only ones currently receiving treatment because of the severity of the condition.
Challenges for the Majority
The remaining 80% of patients don’t experience severe FMR and are not considered for surgery. Unfortunately, they will continue to suffer and likely die since there is no therapeutic option available.
Project Overview
Cardiac Success develops the V-sling system, a transcatheter ventricular repair device aimed at improving cardiac function in HF patients.
Objectives
The objectives of the project are to:
- Finalize product optimization
- Complete verification and validation (V&V) and pre-clinical testing
- Perform the first-in-human (FIH) study
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.500.000 |
| Totale projectbegroting | € 8.531.525 |
Tijdlijn
| Startdatum | 1-5-2022 |
| Einddatum | 30-4-2026 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- CARDIAC SUCCESS LTDpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
A revolutionary technology platform for providing life-saving treatment for end-stage heart failure patientsreBEAT is an innovative heart support technology that safely assists both sides of the heart, aiming to improve treatment accessibility and cost-effectiveness for end-stage heart failure patients. | EIC Accelerator | € 2.499.999 | 2023 | Details |
Innovative, minimally invasive device to support the natural movement of the heart in heart failure patientsSyntach CS is an innovative implantable device that restores natural heart movement in patients with left ventricular heart failure, enhancing cardiac function through synchronized support. | EIC Accelerator | € 2.500.000 | 2022 | Details |
Minimally invasive suturing for vascular bore closure and heart defect repairNovelrad's NVCD closure device aims to minimize complications in large-bore vascular closures during cardiac surgeries through innovative micro-suturing technology, facilitating safer and faster procedures. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Saving patients from severe heart failureThe ICOMS FlowMaker® is a novel intracardiac assist device designed to improve the quality of life for severe heart failure patients, aiming for EU market entry by 2026 through clinical trials. | EIC Accelerator | € 2.500.000 | 2022 | Details |
ContraBand: the only heart failure medical device that is placed outside the heartContraBand is an implantable device designed to restore heart function in CHF patients, aiming for a 2024 launch and generating significant revenue while creating over 95 jobs in Europe. | EIC Accelerator | € 2.499.999 | 2022 | Details |
A revolutionary technology platform for providing life-saving treatment for end-stage heart failure patients
reBEAT is an innovative heart support technology that safely assists both sides of the heart, aiming to improve treatment accessibility and cost-effectiveness for end-stage heart failure patients.
Innovative, minimally invasive device to support the natural movement of the heart in heart failure patients
Syntach CS is an innovative implantable device that restores natural heart movement in patients with left ventricular heart failure, enhancing cardiac function through synchronized support.
Minimally invasive suturing for vascular bore closure and heart defect repair
Novelrad's NVCD closure device aims to minimize complications in large-bore vascular closures during cardiac surgeries through innovative micro-suturing technology, facilitating safer and faster procedures.
Saving patients from severe heart failure
The ICOMS FlowMaker® is a novel intracardiac assist device designed to improve the quality of life for severe heart failure patients, aiming for EU market entry by 2026 through clinical trials.
ContraBand: the only heart failure medical device that is placed outside the heart
ContraBand is an implantable device designed to restore heart function in CHF patients, aiming for a 2024 launch and generating significant revenue while creating over 95 jobs in Europe.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
biomimetic engineered chordae tendineae for valve repair and regenerationThis project aims to develop and validate BioChord, a bioengineered regenerative chordae tendineae for mitral valve repair, enhancing durability and promoting tissue restoration. | ERC Proof of... | € 150.000 | 2023 | Details |
Technology Of Protein delivery in Extracellular Vesicle-induced Cardiac RepairTOP-EVICARE aims to enhance cardiac repair in heart failure by developing innovative protein loading systems in extracellular vesicles, ensuring effective delivery and commercialization. | ERC Proof of... | € 150.000 | 2023 | Details |
Novel microsensing platform for remote patient monitoringThe FORESEE project aims to advance implantable microstimulators for remote monitoring of chronic heart failure, enhancing patient care and market access for 10.5 million potential users. | EIC Transition | € 2.499.051 | 2023 | Details |
SPARK - Subcutaneous Pump and Advanced Remote KitHet project ontwikkelt een innovatief hartondersteuningssysteem met een subcutane sensor voor betere behandeling van gevorderd hartfalen. | Mkb-innovati... | € 199.138 | 2023 | Details |
Dynamic engIneered heart tiSsue to Study intEr-individual susCeptibily and improve Treatment of Heart FailureDISSECT-HF aims to engineer heart tissue from patient-specific stem cells to uncover common mechanisms of heart failure across different etiologies and improve treatment strategies. | ERC Consolid... | € 1.998.775 | 2022 | Details |
biomimetic engineered chordae tendineae for valve repair and regeneration
This project aims to develop and validate BioChord, a bioengineered regenerative chordae tendineae for mitral valve repair, enhancing durability and promoting tissue restoration.
Technology Of Protein delivery in Extracellular Vesicle-induced Cardiac Repair
TOP-EVICARE aims to enhance cardiac repair in heart failure by developing innovative protein loading systems in extracellular vesicles, ensuring effective delivery and commercialization.
Novel microsensing platform for remote patient monitoring
The FORESEE project aims to advance implantable microstimulators for remote monitoring of chronic heart failure, enhancing patient care and market access for 10.5 million potential users.
SPARK - Subcutaneous Pump and Advanced Remote Kit
Het project ontwikkelt een innovatief hartondersteuningssysteem met een subcutane sensor voor betere behandeling van gevorderd hartfalen.
Dynamic engIneered heart tiSsue to Study intEr-individual susCeptibily and improve Treatment of Heart Failure
DISSECT-HF aims to engineer heart tissue from patient-specific stem cells to uncover common mechanisms of heart failure across different etiologies and improve treatment strategies.